Cellectis
CLLS
#7233
Rank
HK$3.73 B
Marketcap
HK$35.94
Share price
-2.53%
Change (1 day)
135.72%
Change (1 year)

P/E ratio for Cellectis (CLLS)

P/E ratio as of December 2025 (TTM): -6.91

According to Cellectis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.91176. At the end of 2022 the company had a P/E ratio of -0.8974.

P/E ratio history for Cellectis from 2015 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2022-0.8974-67.62%
2021-2.77-80.03%
2020-13.995.35%
2019-7.10-16.8%
2018-8.54-17.98%
2017-10.417.95%
2016-8.83-81.69%
2015-48.2

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
uniQure
QURE
-5.86-15.18%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
3.20-146.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
16.3-335.25%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.